Back to Search Start Over

Clinical symptoms in mild cognitive impairment with Lewy bodies: Frequency, time of onset, and discriminant ability.

Authors :
Donaghy, Paul C.
Hamilton, Calum
Durcan, Rory
Lawley, Sarah
Barker, Sally
Ciafone, Joanna
Barnett, Nicola
Olsen, Kirsty
Firbank, Michael
Roberts, Gemma
Lloyd, Jim
Allan, Louise M.
Saha, Ranjan
McKeith, Ian G.
O'Brien, John T.
Taylor, John‐Paul
Thomas, Alan J.
Source :
European Journal of Neurology; Jun2023, Vol. 30 Issue 6, p1585-1593, 9p
Publication Year :
2023

Abstract

Background and purpose: Mild cognitive impairment with Lewy bodies (MCI‐LB) is associated with a range of cognitive, motor, neuropsychiatric, sleep, autonomic, and visual symptoms. We investigated the cumulative frequency of symptoms in a longitudinal cohort of MCI‐LB compared with MCI due to Alzheimer disease (MCI‐AD) and analysed the ability of a previously described 10‐point symptom scale to differentiate MCI‐LB and MCI‐AD, in an independent cohort. Methods: Participants with probable MCI‐LB (n = 70), MCI‐AD (n = 51), and controls (n = 34) had a detailed clinical assessment and annual follow‐up (mean duration = 1.7 years). The presence of a range of symptoms was ascertained using a modified version of the Lewy Body Disease Association Comprehensive LBD Symptom Checklist at baseline assessment and then annually. Results: MCI‐LB participants experienced a greater mean number of symptoms (24.2, SD = 7.6) compared with MCI‐AD (11.3, SD = 7.4) and controls (4.2, SD = 3.1; p < 0.001 for all comparisons). A range of cognitive, parkinsonian, neuropsychiatric, sleep, and autonomic symptoms were significantly more common in MCI‐LB than MCI‐AD, although when present, the time of onset was similar between the two groups. A previously defined 10‐point symptom scale demonstrated very good discrimination between MCI‐LB and MCI‐AD (area under the receiver operating characteristic curve = 0.91, 95% confidence interval = 0.84–0.98), replicating our previous finding in a new cohort. Conclusions: MCI‐LB is associated with the frequent presence of a particular profile of symptoms compared to MCI‐AD. Clinicians should look for evidence of these symptoms in MCI and be aware of the potential for treatment. The presence of these symptoms may help to discriminate MCI‐LB from MCI‐AD. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13515101
Volume :
30
Issue :
6
Database :
Complementary Index
Journal :
European Journal of Neurology
Publication Type :
Academic Journal
Accession number :
163567521
Full Text :
https://doi.org/10.1111/ene.15783